Newer schizophrenia drugs cause heart risks: study

By Gene Emery

BOSTON (Reuters) - Newer “atypical” drugs for schizophrenia and other mental problems, which are supposed to be safer, may in fact carry a greater risk of a fatal heart attack than older medicines, researchers said on Wednesday.

The drugs are among the best-selling in the world and some experts suggested that the common practice of using them for unapproved purposes such as dementia and childhood hyperactivity should be sharply curtailed.

Dr. Wayne Ray of the Vanderbilt University School of Medicine and colleagues studied nearly 277,000 people in Tennessee and found patients taking the highest dose had the greatest risk, and the danger faded once they stopped taking the drugs.

Ray said the findings do not necessarily mean people should stop taking their drugs. In some cases, there are no good alternative treatments.

“Any prescription is a balancing of risks and benefits. This is more information on the risks that needs to be taken into account,” Ray said in a telephone interview.

“Many people thought the “atypicals” would be much, much safer. Our study suggests that they are not at all safer in regards to this serious end point,” said Ray.

In June the U.S. Food and Drug Administration said older, conventional antipsychotic medications should carry a warning on the packaging about the risk of death.

The FDA issued a similar warning in 2005 for newer antipsychotic’s such as Bristol-Myers Squibb Co’s and Otsuka Pharmaceutical Group’s Abilify and Eli Lilly and Co’s Zyprexa, known generically as olanzapine.

Using files from the Tennessee Medicaid program for the poor, the researchers confirmed that the rate of fatal heart attacks was twice as high among those taking the drugs.

“A similar increased risk was seen for current users of atypical antipsychotic drugs, who had a rate of sudden cardiac death that was more than twice that for nonusers,” they wrote.

The drugs studied in this group included clozapine, made generically, Johnson & Johnson’s Risperdal, or risperidone, Zyprexa, and quetiapine, made by AstraZeneca under the brand name Seroquel.

Zyprexa, Risperdal and Seroquel are among the 10 top-selling drugs worldwide, with a combined sales volume of $14.5 billion in 2007. Lilly and AstraZeneca did not immediately respond to requests for comment.

The drugs can interfere with the flow of potassium, which the heart needs to function properly.

Ray said that in spite of the risks, there are no good alternatives for schizophrenia and other serious psychoses. “The take-home message from our study is for these diseases you would first want careful testing, like an EKG (electrocardiogram) and a cardiovascular workup,” he said.

The antipsychotics are often prescribed for bipolar disorder, anxiety, depression and attention-deficit hyperactivity disorder (ADHD), even though their use for those purposes is not approved by the FDA.  Continued…

Source

--------------------------------------------------------------------------------------------
Related Posts:


By Julie Steenhuysen CHICAGO (Reuters) - Patients taking blood pressure drugs known as beta blockers had double the risk of heart attack after surgery and more than double the risk of dying within a month of the operation, U.S. researchers said on Monday. Beta blockers are often given to slow a patient’s heart rate before routine operations

Full Post: Blood pressure drug before surgery raises risks
--------------------------------------------------------------------------------------------

By Julie Steenhuysen CHICAGO (Reuters) - Older diabetics who took GlaxoSmithKline’s Avandia to control their blood sugar had a higher risk of death and heart failure while on the drug than those who took Takeda Pharmaceutical’s Actos, a drug in the same class, U.S. researchers said on Monday. They said the head-to-head comparison confirms prior analyses finding

Full Post: Safety risks higher with Avandia than Actos: study
--------------------------------------------------------------------------------------------

LONDON (Reuters) - Antipsychotic drugs prescribed to treat aggression in older Alzheimer’s patients appear to significantly raise their risk of dying prematurely, British researchers said Friday. The results from the first long-term study on the effect of the medicines on people with Alzheimer’s highlights the need to seek less harmful treatments for many of these patients,

Full Post: Antipsychotics for Alzheimer’s up death risk: study
--------------------------------------------------------------------------------------------

By Will Dunham WASHINGTON (Reuters) - Nearly 20 percent more U.S. men over 50 and women over 60 stand to benefit from taking statins, based on the findings of a recent study on the cholesterol-lowering drugs, U.S. researchers said on Tuesday. Their research stakes out a potentially expanded market for statins, already the world’s top-selling drugs. The so-called

Full Post: Statins may help millions more people: study
--------------------------------------------------------------------------------------------

By Will Dunham WASHINGTON (Reuters) - The U.S. death rates from heart disease and stroke have fallen by about 30 percent this decade but there are ominous signs that the worrisome obesity epidemic could snuff out the progress, experts said on Monday. Better control of cholesterol and blood pressure, declining smoking rates and better medical treatments all

Full Post: U.S. stroke, heart disease death rates down sharply

Site Navigation

Most Read

Search